

Lucence Diagnostics opens new HQ and Lab in Singapore

30 January 2019 | News | By Manbeena Chawla

Launches LiquidHALLMARK®, the first blood test in the world that detects mutations and viruses for 14 types of cancers.



Lucence Diagnostics has recently announced the opening of its new headquarters and molecular diagnostics laboratory in Singapore. The opening was officiated by Dr Koh Poh Koon, Senior Minister of State, Ministry of Trade and Industry.

Lucence has expanded its business operations to Hong Kong and San Francisco. Its blood tests are currently available in 8 countries in the region – India, Hong Kong, Philippines, Malaysia, Myanmar, Thailand, Vietnam and Singapore. Lucence's new 10,000 square feet facility will help the company scale up its R&D operations, meet the growing demand for its clinical services, and expand to new markets.

The company has also launched its latest flagship blood test LiquidHALLMARK®. This new test is able to detect 14 types of cancers, 50 genetic mutations and 2 viruses. It is the world's first blood test that simultaneously detects both cancer-causing genetic mutations and viruses with 99.9% accuracy. This test delivers comprehensive molecular profiling of tumor with one draw of blood using Lucence's proprietary amplicon-based sequencing technology AmpliMARK™. It detects DNA fragments from cancerous tumors that circulate in the blood to identify tumor-specific genetic mutations, as well as viruses like Hepatitis B, which is associated with liver cancer, and Epstein-Barr, which is associated with nose cancer.

LiquidHALLMARK® will help physicians select the right targeted therapies and immunotherapies for their patients. It will also match patients to clinical trials of new treatments that may help them. This treatment recommendation system is supported by Lucence's artificial intelligence platform SunTzu.AI™, which integrates clinical data from diverse sources, to develop a personalized treatment strategy for each patient.

Lucence is now also developing a blood test for the early detection of multiple cancers to save lives. The company will launch a clinical study with 100,000 participants across Asia to validate its early cancer detection test this year.

"Lucence's vision is to achieve zero avoidable cancer deaths through early detection and better treatment selection. Our expanded molecular diagnostics laboratory will be the foundation of that vision. We are glad to have improved the lives of

thousands of patients in Asia with our range of blood tests for cancer screening and treatment selection. We will continue to innovate because we want to achieve early detection for all types of cancers to truly save lives,” said Dr. Tan Min-Han.